Aldeyra Therapeutics will initiate the phase 3 INVIGORATE trial of topical ocular reproxalap following positive results from an allergen chamber clinical methods trial, according to a press release.
Expanded results of the double-masked, randomized, vehicle-controlled, crossover allergen chamber clinical methods trial found highly statistically significant activity relative to vehicle in all symptoms and signs, the release said. Ocular itching and tearing, reported by patients, as well as ocular redness, were recorded at various intervals over 3.5 hours of ragweed exposure during the trial.
Uncategorized